Last reviewed · How we verify
NPH/Regular 70/30 mix
NPH/Regular 70/30 mix is a Insulin combination Small molecule drug developed by Dennis G. Karounos, M.D.. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Novolin 70/30.
This insulin mixture combines intermediate-acting NPH insulin with rapid-acting regular insulin to provide both basal and mealtime glucose control in diabetes.
NPH (Neutral Protamine Hagedorn) insulin and regular insulin are mixed in a 70/30 ratio, which is a type of insulin combination used to manage diabetes mellitus, type 2, among other conditions such as atherosclerosis, cardiovascular diseases, hypercholesterolemia, and hypertension. This insulin combination is classified as a small molecule modality, specifically used as an anti-hyperglycemic agent.
At a glance
| Generic name | NPH/Regular 70/30 mix |
|---|---|
| Also known as | Novolin 70/30 |
| Sponsor | Dennis G. Karounos, M.D. |
| Drug class | Insulin combination |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
NPH (neutral protamine Hagedorn) insulin is an intermediate-acting insulin that provides sustained glucose lowering over 12-24 hours, while regular (soluble) insulin is a short-acting insulin that rapidly lowers blood glucose after meals. The 70/30 formulation delivers 70% NPH and 30% regular insulin in a single injection, allowing patients to achieve both background insulin coverage and postprandial glucose control with a fixed-ratio combination.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Veterans Inpatient Insulin Study and Transition to Outpatient Therapy (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPH/Regular 70/30 mix CI brief — competitive landscape report
- NPH/Regular 70/30 mix updates RSS · CI watch RSS
- Dennis G. Karounos, M.D. portfolio CI
Frequently asked questions about NPH/Regular 70/30 mix
What is NPH/Regular 70/30 mix?
How does NPH/Regular 70/30 mix work?
What is NPH/Regular 70/30 mix used for?
Who makes NPH/Regular 70/30 mix?
Is NPH/Regular 70/30 mix also known as anything else?
What drug class is NPH/Regular 70/30 mix in?
What development phase is NPH/Regular 70/30 mix in?
What are the side effects of NPH/Regular 70/30 mix?
What does NPH/Regular 70/30 mix target?
Related
- Drug class: All Insulin combination drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Dennis G. Karounos, M.D. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Novolin 70/30
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing